Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Central Nervous System Biomarkers Market, by region, 2019-2029 (USD Billion)
1.2.2. Central Nervous System Biomarkers Market, by Type, 2019-2029 (USD Billion)
1.2.3. Central Nervous System Biomarkers Market, by Application, 2019-2029 (USD Billion)
1.2.4. Central Nervous System Biomarkers Market, by End User, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Central Nervous System Biomarkers Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Central Nervous System Biomarkers Market Dynamics
3.1. Central Nervous System Biomarkers Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing incidence of neurological disorders
3.1.1.2. Increasing Research and Development with Successful Clinical Trials of Biomarkers
3.1.2. Market Challenges
3.1.2.1. High Cost of Central Nervous System Biomarkers
3.1.3. Market Opportunities
3.1.3.1. Increased development in genomics, proteomics, and imaging systems
3.1.3.2. Burgeoning investments from the government and players
Chapter 4. Global Central Nervous System Biomarkers Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economic
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Central Nervous System Biomarkers Market, by Type
6.1. Market Snapshot
6.2. Global Central Nervous System Biomarkers Market by Type, Performance – Potential Analysis
6.3. Global Central Nervous System Biomarkers Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Central Nervous System Biomarkers Market, Sub Segment Analysis
6.4.1. Safety Biomarkers
6.4.2. Efficacy Biomarkers
6.4.3. Validation Biomarkers
6.4.4. Others
Chapter 7. Global Central Nervous System Biomarkers Market, by Application
7.1. Market Snapshot
7.2. Global Central Nervous System Biomarkers Market by Application, Performance – Potential Analysis
7.3. Global Central Nervous System Biomarkers Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
7.4. Central Nervous System Biomarkers Market, Sub Segment Analysis
7.4.1. Drug Discovery and Development
7.4.2. Personalized Medicine
7.4.3. Other Applications
Chapter 8. Global Central Nervous System Biomarkers Market, by End User
8.1. Market Snapshot
8.2. Global Central Nervous System Biomarkers Market by End User, Performance – Potential Analysis
8.3. Global Central Nervous System Biomarkers Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
8.4. Central Nervous System Biomarkers Market, Sub Segment Analysis
8.4.1. Diagnostic Labs
8.4.2. Clinics/Hospitals
8.4.3. Research Centers
Chapter 9. Global Central Nervous System Biomarkers Market, Regional Analysis
9.1. Central Nervous System Biomarkers Market, Regional Market Snapshot
9.2. North America Central Nervous System Biomarkers Market
9.2.1. U.S. Central Nervous System Biomarkers Market
9.2.1.1. Type breakdown estimates & forecasts, 2019-2029
9.2.1.2. Application breakdown estimates & forecasts, 2019-2029
9.2.1.3. End User breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Central Nervous System Biomarkers Market
9.3. Europe Central Nervous System Biomarkers Market Snapshot
9.3.1. U.K. Central Nervous System Biomarkers Market
9.3.2. Germany Central Nervous System Biomarkers Market
9.3.3. France Central Nervous System Biomarkers Market
9.3.4. Spain Central Nervous System Biomarkers Market
9.3.5. Italy Central Nervous System Biomarkers Market
9.3.6. Rest of Europe Central Nervous System Biomarkers Market
9.4. Asia-Pacific Central Nervous System Biomarkers Market Snapshot
9.4.1. China Central Nervous System Biomarkers Market
9.4.2. India Central Nervous System Biomarkers Market
9.4.3. Japan Central Nervous System Biomarkers Market
9.4.4. Australia Central Nervous System Biomarkers Market
9.4.5. South Korea Central Nervous System Biomarkers Market
9.4.6. Rest of Asia Pacific Central Nervous System Biomarkers Market
9.5. Latin America Central Nervous System Biomarkers Market Snapshot
9.5.1. Brazil Central Nervous System Biomarkers Market
9.5.2. Mexico Central Nervous System Biomarkers Market
9.5.3. Rest of Latin America Central Nervous System Biomarkers Market
9.6. Rest of The World Central Nervous System Biomarkers Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Acumen Pharmaceuticals Inc.
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Alseres Pharmaceuticals Inc.
10.2.3. vacta Life Sciences Limited
10.2.4. Biomeriux (Banyan Biomarkers Inc.)
10.2.5. Bio-Rad Laboratories Inc.
10.2.6. G-Biosciences
10.2.7. Merck KGaA
10.2.8. Thermo Fisher Scientific Inc.
10.2.9. Eli Lilly and Company (Avid radiopharmaceuticals Inc.)
10.2.10. Proteome Sciences PLC (Service)
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/